Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients (IFM 2018-04)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03606577
Recruitment Status : Recruiting
First Posted : July 31, 2018
Last Update Posted : October 24, 2019
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:
According to international guidelines, upfront therapy for transplant eligible myeloma patients should include triplet induction containing proteasome inhibitor and immunomodulatory agent, autologous stem cell transplant, PI+Imid based triplet consolidation and lenalidomide maintenance. Despite this approach, virtually all MM patients experience disease relapse, especially those with High Risk disease defined by adverse cytogenetic abnormalities (i.e. del(17p), or t(14;16) or t(4;14)) detected by FISH and/or SNP arrays. Indeed, HR myeloma is associated with poorer progression free survival and overall survival and frontline therapy should therefore be improved for this subset of HR patients. The primary objective of this prospective multicenter, open label, interventional phase 2 trial is to evaluate the feasibility of an intensive program including quadruplet induction and consolidation, tandem autologous stem cell transplantation and maintenance in newly diagnosed multiple myeloma patients presenting with HR cytogenetic. Quadruplet induction and consolidation include carfilzomib, lenalidomide, dexamethasone and daratumumab. Maintenance will include lenalidomide and daratumumab. Secondary objectives will include efficacy parameters (i.e. response rate, minimal residual disease, safety, progression free survival, overall survival).

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Carfilzomib Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Intervention Model Description: One group of subjects who must have documented Multiple Myeloma High Risk satisfying the CRAB and measurable disease.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergroupe Francophone du Myélome "IFM 2018-04"
Actual Study Start Date : July 30, 2019
Estimated Primary Completion Date : February 2, 2021
Estimated Study Completion Date : November 2, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone Drug: Carfilzomib
Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)

Drug: Daratumumab
induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 & D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)

Drug: Lenalidomide
induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)

Drug: Dexamethasone
induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22




Primary Outcome Measures :
  1. Percentage of patients receiving the second Autologous Stem Cell Transplant [ Time Frame: 15 months ]

Secondary Outcome Measures :
  1. Number of adverse events [ Time Frame: 48 months ]
  2. Number of responses [ Time Frame: 48 months ]
  3. Number of MRD [ Time Frame: 48 months ]
  4. Number of death [ Time Frame: 84 months ]
  5. Percentage of time to progression [ Time Frame: 84 months ]
  6. Number of patients having survival without progress [ Time Frame: 84 months ]
  7. Percentage duration of response [ Time Frame: 84 months ]
  8. Number of cells collected [ Time Frame: 168 days ]
  9. percentage of value of biological prognostic factors [ Time Frame: 48 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects, 18 years of age or older, younger than 66 years (< 66 years)
  2. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
  3. Subject must have documented multiple myeloma satisfying the Diagnostic criteria for symptomatic Myelome Multiple and measurable disease as defined by:

    • Monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma AND any one or more of the following myeloma defining events:

      • Hypercalcemia: serum calcium > 0.25 mmol/L higher than ULN or > 2.75 mmol/L
      • Renal insufficiency: creatinine clearance < 40mL/min or serum creatinine > 177 μmol/L
      • Anemia: hemoglobin > 2 g/dL below the lower limit of normal or hemoglobin < 10 g/dL
      • Bone lesions: one or more osteolytic lesions on skeletal radiography, CT or PET-CT
      • Clonal bone marrow plasma cell percentage ≥ 60%
      • Involved: uninvolved serum free light chain ratio ≥ 100
      • Superior 1 focal lesion on MRI studies
    • Measurable disease as defined by the following:

    M-component ≥ 5g/l, and/or urine M-component ≥ 200 mg/24h and/or serum Free Light Chain ≥ 100 mg/l.

  4. Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation
  5. Subject must have high risk disease according to FISH analysis: del(17p), or t(14;16) or t(4;14). The FISH-positivity cut-off value for defining the presence of del(17p) in this study is 50%
  6. Karnofsky performance status score ≥ 50%
  7. Women of childbearing potential must have a negative serum or urine pregnancy test within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control used at the same time, beginning at least 4 weeks before initiation of lenalidomide treatment and continuing for at least 30 days after the last dose of Lenalidomide. Women must also agree to notify pregnancy or doubt upon pregnancy during the study.
  8. Men must agree to not father a child and agree to use a latex condom during therapy and for 4 weeks after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential.
  9. Subject must have pretreatment clinical laboratory values meeting the following criteria during the Screening Phase (Lab tests should be repeated if done more than 15 days before C1D1):

    1. Hemoglobin ≥ 7.5 g/dL. Prior red blood cell transfusion or recombinant human erythropoietin use is permitted;
    2. Absolute neutrophil count ≥ 1.0 Giga/l (GCSF use is permitted);
    3. ASAT ≤ 3 x ULN;
    4. ALAT ≤ 3 x ULN;
    5. Total bilirubin ≤ 3 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubin ≤ 1.5 x ULN);
    6. Calculated creatinine clearance ≥ 40 mL/min/1.73 m² ;
    7. Corrected serum calcium ≤ 14 mg/dL; or free ionized calcium ≤6.5 mg/dL;
    8. Platelet count ≥ 50 Giga/l for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; otherwise platelet count > 50 Giga/l (transfusions are not permitted to achieve this minimum platelet count).
  10. Affiliation with French social security system or beneficiary from such system

Exclusion Criteria:

  1. Subjects must not have been treated previously with any systemic therapy for multiple myeloma. Prior treatment with corticosteroids or radiation therapy does not disqualify the subject (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone in a 2-week period). Two weeks must have elapsed since the date of the last radiotherapy treatment. Enrolment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy
  2. Subject has received daratumumab or other anti-CD38 therapies previously
  3. Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma.
  4. Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  5. Subject has had plasmapheresis within 28 days of C1D1.
  6. Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.
  7. Myocardial infarction within 6 months prior to enrolment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  8. Uncontrolled hypertension
  9. Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume (FEV1) in 1 second < 50% of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal.
  10. Subjects with a history of moderate or severe persistent asthma within the past 2 years, or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
  11. Subject has plasma cell leukemia (according to WHO criterion: ≥ 20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 × 10^9/L) or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome.
  12. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (as clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (as rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, fosphenytoin phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment.
  13. Known intolerance to steroid therapy
  14. History of hypersensitivity to any of the study medications, their analogues, or excipients in the various formulations, or to study-required co medication
  15. Subject has had major surgery within 2 weeks before the first dose of study treatment or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Kyphoplasty or Vertebroplasty are not considered major surgery.
  16. Clinically relevant active infection or serious co-morbid medical conditions
  17. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years.
  18. Female subject who is pregnant or breast-feeding + male and female refusing birth control conditions
  19. Serious medical or psychiatric illness likely to interfere with participation in study
  20. Uncontrolled diabetes mellitus
  21. Known HIV infection; Known active hepatitis B or C viral infection; or other ongoing uncontrolled infection
  22. Incidence of gastrointestinal disease that may significantly after the absorption of oral drugs
  23. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
  24. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03606577


Locations
Layout table for location information
France
CHU de Nantes Recruiting
Nantes, Pays De La Loire, France, 44000
Contact: Philippe Moreau, MD    02.40.08.32.71 ext +33    philippe.moreau@chu-nantes.fr   
CHU Caen Not yet recruiting
Caen, France
Contact: Macro         
CHRU Dijon Not yet recruiting
Dijon, France
Contact: Caillot         
CHRU - Hôpital A.Michallon Not yet recruiting
Grenoble, France
Contact: Mariette         
CHD Vendée Not yet recruiting
La Roche-sur-Yon, France
Contact: Tiab         
CHRU - Hôpital Claude Huriez Not yet recruiting
Lille, France
Contact: Manier         
CH de Lyon Sud Not yet recruiting
Lyon, France
Contact: KARLIN         
CHRU Hôpital du Haut Lévêque Not yet recruiting
Pessac, France
Contact: Hulin cyrille         
CHRU - Hôpital de Pontchaillou Not yet recruiting
Rennes, France
Contact: Escoffre         
CHU Toulouse Not yet recruiting
Toulouse, France
Contact: Attal         
CHRU Bretonneau Not yet recruiting
Tours, France
Contact: Benbouker Lofti         
Contact    02 47 47 38 27      
CHRU - Hôpitaux de Brabois Not yet recruiting
Vandoeuvre les nancy, France
Contact: PErrot         
Sponsors and Collaborators
Nantes University Hospital

Layout table for additonal information
Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT03606577     History of Changes
Other Study ID Numbers: RC18_0206
First Posted: July 31, 2018    Key Record Dates
Last Update Posted: October 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nantes University Hospital:
Multiple Myeloma
Newly Diagnosed
High Risk
Revlimid
Carfilzomib
Daratumumab
Dexaméthasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Daratumumab
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Dexamethasone acetate
Lenalidomide
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal